<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157481</url>
  </required_header>
  <id_info>
    <org_study_id>DEMAND-01</org_study_id>
    <secondary_id>UMIN000003856</secondary_id>
    <nct_id>NCT01157481</nct_id>
  </id_info>
  <brief_title>Diastolic Heart Failure Management by Nifedipine</brief_title>
  <acronym>DEMAND</acronym>
  <official_title>Diastolic Heart Failure Management by Nifedipine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Demand Investigators</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Demand Investigators</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure with preserved ejection fraction have a equally high risk for
      mortality and re-hospitalization as those with reduced ejection fraction. Effective
      management strategies are critically needed to be established for this type of heart failure.
      These patients have more hypertensive and ischemic etiology than those with reduced ejection
      fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the
      heart failure clinical composite response endpoint compared with the conventional treatment
      in patients with heart failure with hypertension and/or coronary artery disease and preserved
      ejection fraction (&gt;=50%) by echocardiography. This study is multi-center, prospective,
      randomized, open-label, and blinded-endpoint design.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart failure clinical composite response endpoint</measure>
    <time_frame>up to 53 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for cardiovascular disease</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for worsening heart failure</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for acute myocardial infarction, angina, coronary artery bypass grafting and percutaneous coronary intervention</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 53 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conventional therapy plus nifedipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy plus nifedipine</intervention_name>
    <description>Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014</description>
    <arm_group_label>Conventional therapy plus nifedipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Conventional therapy</description>
    <arm_group_label>Conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20 years and older

          2. Heart failure with history of hypertension and/or coronary artery disease

          3. LVEF &gt; or = 50% on echocardiography

        Exclusion Criteria:

          1. Valvular heart diseases with significant regurgitation and/or stenosis

          2. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right
             ventricular cardiomyopathy, and active myocarditis

          3. Constrictive pericarditis

          4. Cardiogenic shock

          5. Planned coronary artery bypass grafting or percutaneous coronary intervention within 3
             months

          6. History of acute coronary syndrome or stroke within 3 months

          7. Pregnancy or breastfeeding

          8. Hypersensitivity or contraindication to nifedipine

          9. Inability to obtain informed consent

         10. Any conditions not suitable for the participation in this trial judged by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hokkaido Univestity Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diastolic Heart Failure</keyword>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>nifedipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

